RxDoctor Payments Data

Derrick Walker, MD

Family Medicine · Indianapolis, INNPI 1760611529

Payments from drug & device makers

$3,470in general payments, 2019–2025

Across 197 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$835
  • AstraZeneca$572
  • Lilly USA, LLC$510
  • Pfizer$210
  • Astellas Pharma US Inc$175
  • AbbVie$142
  • plus $1K from 23 others

What the payments were for

  • Food & beverage$3,470100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,470 in reported general payments places this provider in the 80th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$61,765
Medicare patients
172
Services billed
675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide195$347,993
MounjaroTirzepatide110$139,580
JardianceEmpagliflozin59$71,235
Trelegy ElliptaFluticasone/Umeclidin/Vilanter67$63,844
TrulicityDulaglutide36$57,975
RybelsusSemaglutide36$50,584
FarxigaDapagliflozin Propanediol39$45,956
Tresiba Flextouch U-200Insulin Degludec12$43,544
EliquisApixaban38$39,030
XareltoRivaroxaban50$35,010
LinzessLinaclotide20$15,337
Spiriva RespimatTiotropium Bromide14$14,030
Breo ElliptaFluticasone/Vilanterol13$10,284
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$8,588
ShingrixVaricella-Zoster Ge/As01b/Pf34$7,424

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$835$398,577231 claims
Lilly USA, LLCMounjaro, Trulicity$510$197,555146 claims
Boehringer IngelheimJardiance, Spiriva Respimat$110$85,26573 claims
GSKTrelegy Ellipta, Breo Ellipta, Shingrix$72$81,553114 claims
AstraZenecaFarxiga$572$45,95639 claims
PfizerEliquis, Abrysvo$210$44,39655 claims
AbbVieLinzess, Restasis$142$19,08031 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Indianapolis

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →